Wechselwirkungen · Vfend
VFEND 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 46–47
HOS-109547 · Präparat HOS-093201
46 Ergot derivatives Ergot alkaloids (including but Although not studied, voriconazole Contraindicated (see section not limited to: ergotamine and is likely to increase the plasma 4.3) dihydroergotamine) concentrations of ergot alkaloids [CYP3A4 substrates] and lead to ergotism. GI motility agents Cisapride Although not studied, increased Contraindicated (see section [CYP3A4 substrate] plasma concentrations of cisapride 4.3) can lead to QTc prolongation and rare occurrences of torsades de pointes. Herbal medicines St. John’s Wort In an independent published study, Contraindicated (see section [CYP450 inducer; Voriconazole AUC0- 59% 4.3) P-gp inducer] 300 mg TID (coadministered with voriconazole 400 mg single dose)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) ergot alkaloids (HOS-108807) lead (HOS-085592) ergotamine (HOS-086154) dihydroergotamine (HOS-086152)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 8e184b150a415126cf8ae17277d9a0f240f7a1a18fa73708804b9ed7e1702539 · Zeichen 22478–23419 im Abschnitt